Meeting
2017 ASCO Annual Meeting
Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting.
Authors
Jordi Remon
Medical Oncology Department, Gustave Roussy, Villejuif, France
Jordi Remon , Benjamin Besse , Ludovic Lacroix , Laura Mezquita , Cecile Jovelet , Karen Howarth , Vincent Plagnol , Clive D. Morris , Claudio Nicotra , Chloe Pannet , Emma Green , Jean-Charles Soria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11532)
DOI
10.1200/JCO.2017.35.15_suppl.11532
Abstract #
11532
Poster Bd #
232
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay.
First Author: Jonathan Poh
Poster
2017 ASCO Annual Meeting
Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC).
First Author: Penelope Ann Bradbury
Poster
2023 ASCO Annual Meeting
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).
First Author: Christian Diego Rolfo
Poster
2023 ASCO Annual Meeting
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
First Author: Aurélie Swalduz